4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
← catalyst calendarSponsored by 4D Molecular Therapeutics (industry) · FDMT — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
21actual
Sites
8
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-06-09 | actual | When the study began enrolling |
| Primary completion | Jun 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2020-08-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- X-Linked Retinitis Pigmentosa
Interventions
- Biological: 4D-125 IVT Injection
- Other: Observational
Primary outcome
what the primary-completion date above is the date OFIncidence and severity of TEAEs and serious adverse events (SAEs), including clinically significant changes in safety parameters
measured 24 months to 60 Months
Permalink · FDMT's whole pipeline · Catalyst calendar · Every registered study · What changed